Sermorelin Peptide: Research Overview, Purity Data and Where to Buy

Sermorelin isn't growth hormone. It's a 29-amino-acid fragment of the hormone that tells the pituitary to release its own, and that single structural fact reshapes every research question that follows, from how plasma sampling gets timed to why a vial loses activity the way it does.

We supply research-grade sermorelin to laboratories, and the questions we field most often have nothing to do with mechanism. They're about lot-to-lot consistency, why HPLC purity and net peptide content are two different numbers, and what a certificate of analysis actually proves about the material in the vial. All products are sold for laboratory research use only and are not for human consumption.

What is sermorelin?

Sermorelin is the acetate salt of GHRH(1-29)NH2, the first 29 amino acids of human growth hormone-releasing hormone and the shortest fragment that retains full activity at the GHRH receptor. In research models it signals somatotroph cells of the anterior pituitary to synthesise and release endogenous growth hormone. Its molecular weight sits near 3,358 daltons.

The oversimplification worth correcting is the idea that sermorelin raises growth hormone the way recombinant GH does. It doesn't. It acts one step upstream, so the gland's own brakes, somatostatin tone and IGF-1 negative feedback, still set the ceiling on any response observed. This page covers the receptor mechanism, what published literature examines, laboratory handling and storage, how purity is verified lot by lot, regulatory status, and where to buy sermorelin for research.

A 29-amino-acid fragment that signals the pituitary, not the liver

Sermorelin belongs to the growth hormone secretagogue class and, within it, to the GHRH analogue subgroup: compounds that bind the growth hormone-releasing hormone receptor (GHRHR) rather than imitating growth hormone itself. GHRHR is a class B G-protein-coupled receptor expressed densely on somatotroph cells of the anterior pituitary. When the receptor is occupied, the Gs alpha subunit activates adenylyl cyclase, intracellular cAMP rises, protein kinase A is activated, and transcription driven by the pituitary-specific factor Pit-1 increases both growth hormone synthesis and release.

That second word carries the weight. Synthesis and release. Exogenous recombinant GH floods the circulation and bypasses the gland entirely; a GHRH analogue works through it, which means the response stays bounded by hypothalamic somatostatin (SRIF) tone and by IGF-1 feedback from the liver. In research models, that's the difference between a pulse and a plateau.

Sermorelin's plasma survival is short, measured in minutes rather than hours, and the reason is enzymatic. Dipeptidyl peptidase-4 (DPP-4) clips the Tyr1-Ala2 bond at the N-terminus and inactivates the fragment almost immediately. That vulnerability is the entire design brief behind every analogue that came after it. CJC-1295 without DAC, often written as modified GRF (1-29), carries four amino acid substitutions including D-alanine at position 2 specifically to blunt that cleavage.

In our experience fielding technical questions from research buyers, the DPP-4 detail is the one that reframes how people think about sermorelin. It isn't a weaker compound than its successors. It's the unmodified parent sequence, and comparing the two without accounting for enzymatic half-life produces results that look contradictory when they're simply measuring different clearance curves.

What the published literature on GHRH(1-29) actually examines

Published work on sermorelin clusters into a few recognisable areas rather than spreading evenly across the growth hormone field. The largest body of it concerns pituitary function assessment: using a GHRH analogue as a provocative stimulus to help distinguish whether impaired growth hormone output originates in the hypothalamus or in the pituitary itself. The shape of the indexed literature is visible through the PubMed sermorelin record set and the broader GHRH(1-29) query.

A second cluster concerns growth hormone insufficiency. A 2006 review in Clinical Interventions in Aging discussed GHRH-analogue approaches to adult-onset growth hormone insufficiency and the argument that stimulating endogenous secretion preserves feedback architecture that exogenous hormone bypasses (PubMed).

A third cluster sits around ageing and the so-called somatopause, where investigators examined GHRH(1-29) and changes in the GH/IGF-1 axis in older adults (PubMed search).

Two honest caveats belong here. Much of the sermorelin literature predates current standardisation of growth hormone assays, so cross-study comparison is harder than the citation trail suggests. And findings in clinical papers are findings, not instructions. Research suggests directions worth testing; none of it constitutes guidance for anyone outside a controlled research setting.

Handling, storage and the cold chain that decides whether a vial is usable

Lyophilised sermorelin is a dry amorphous powder, and in that state it's comparatively durable when kept cold, dark and dry. The standard laboratory condition for long-term storage of lyophilised peptides is −20°C or colder, protected from light. Brief ambient excursions during transit are generally tolerated by dry material, which is why peptides ship the way they do, but that tolerance belongs to the powder, not to the solution.

Once sermorelin is in solution, the clock changes entirely. Solutions are held refrigerated at 2–8°C and are far more vulnerable: hydrolysis, oxidation of the N-terminal tyrosine residue, and aggregation all accelerate in the liquid state. Repeated freeze-thaw cycling is the most avoidable cause of lost activity, because every cycle drives aggregation at the air-liquid interface.

Here's the part that catches people. Denaturation is invisible. A solution that has been through a temperature excursion looks identical to one that hasn't. No colour change, usually no precipitate, nothing to see. The only reliable detection is analytical, which is why storage discipline substitutes for testing most labs can't run per vial.

Aliquoting into single-use volumes before freezing, labelling every aliquot with lot and date, and keeping vials in the body of the freezer rather than in the door are unglamorous habits that preserve more material than any clever choice of solvent. Sermorelin is not uniquely fragile among research peptides. It isn't forgiving either.

Purity, net peptide content, and what a certificate of analysis really proves

Purity, for sermorelin or any research peptide, means one specific thing: the area percentage of the main peak in reverse-phase HPLC (high-performance liquid chromatography), usually read at 214 or 220 nm where the peptide bond absorbs. Identity is a separate test. Mass spectrometry, typically ESI-MS or MALDI-TOF, confirms the observed molecular mass matches the theoretical mass of the stated sequence. A lot with only one of those two tests has been described, not verified.

Now the detail most buyers never hear. HPLC purity and net peptide content are different numbers, and the gap between them is not trivial. Solid-phase synthesis using Fmoc chemistry leaves trifluoroacetic acid (TFA) counterions bound to basic residues, and lyophilised powder retains bound water on top of that. So a vial can read 99% pure by HPLC and still contain noticeably less actual peptide by mass than the label weight, with the balance being salt and water. Purity describes what fraction of the peptide present is the correct peptide. Net peptide content, determined by amino acid analysis or nitrogen determination, describes how much peptide is present at all. Research that treats the first number as though it were the second bakes error into its calculations before the first run.

That's why per-lot documentation beats a generic specimen document. Every lot of sermorelin we supply is produced through small-batch synthesis with exact amino-acid sequencing and ships with lot-specific analytical paperwork; our certificates of analysis are published per lot. If the sermorelin lot number stamped on the vial doesn't appear on the certificate, that document describes somebody else's material.

How sermorelin compares with other growth hormone secretagogues

Not every compound that raises growth hormone in a research model does it through the same receptor, and conflating them is the most common error in secretagogue study design. This table sets sermorelin against the three compounds it's most often placed alongside.

What If: Common Laboratory Scenarios

What if a vial arrived warm after a shipping delay?

Document the arrival condition, note the lot, and treat the material as suspect rather than discarding it on sight. Lyophilised sermorelin tolerates brief ambient exposure better than solution does, because water is the medium through which hydrolysis and oxidation proceed. If the powder arrived dry and intact, short transit warmth is usually a minor variable. If the shipment was delayed for days in heat, the only honest answer is that activity is now unknown without analytical confirmation.

What if the certificate of analysis doesn't list a lot number?

Treat an unnumbered certificate as marketing material, not documentation. A certificate without a lot identifier cannot be tied to the vial in front of you, which defeats its entire purpose. Lot-specific HPLC traces and mass spectrometry reports for sermorelin and every other catalogue compound are published per lot at our certificates of analysis page precisely so the vial and the paperwork can be matched.

What if the powder looks like a thin film rather than a visible cake?

Check the stated milligram content on the certificate before assuming anything went wrong. Lyophilisation produces wildly different visual results depending on fill volume, freezing rate and the shelf profile used, and a small quantity of sermorelin can present as a barely visible residue on the vial wall. Appearance is not a potency indicator in either direction.

What if a GHRH analogue produces a much smaller response than an earlier run?

Look at the timing of the run before you question the material. Somatostatin tone oscillates, and the same quantity of a GHRH analogue applied during a somatostatin trough versus a peak produces markedly different output in research models. This is the single most underappreciated confounder in sermorelin work: investigators chase a supply problem when they're actually sampling across different points of an endogenous rhythm.

The uncomfortable truth about sourcing research peptides

Here's the honest answer: in this market, the compound is rarely the variable that decides whether a result replicates. The supplier is. Two vials labelled sermorelin at the same stated purity can differ in net peptide content, counterion load, residual solvent and aggregation state, and not one of those differences is visible through glass. If a supplier can't produce a lot-matched HPLC trace and a mass spectrometry report on request, the number printed on the label is a claim rather than a measurement. We mean that sincerely, and it applies to us as much as to anyone else.

Regulatory status and where to buy sermorelin for research

Sermorelin acetate carries a regulatory history worth stating plainly. It was marketed in the United States under the brand name Geref and was withdrawn from that market in 2008. Research-grade sermorelin supplied today is not that drug product, is not an approved medicine, and is not supplied for human or veterinary use of any kind. It is a laboratory reagent and nothing else. If a question concerns a person's health, it belongs with a physician; if it concerns an animal, talk to your veterinarian rather than treating a research catalogue as a source of care advice.

Real Peptides produces each compound through small-batch synthesis with exact amino-acid sequencing, verifies identity and purity lot by lot, and publishes the resulting analytical documentation rather than a single representative specimen. The sermorelin product page lists the specification and the lot documentation that ships with the material.

Researchers comparing GHRH analogues alongside sermorelin usually look at CJC-1295 without DAC, tesamorelin and the GHSR-1a-selective ipamorelin; the full catalogue sits in our shop, lot documentation lives at certificates of analysis, our synthesis and verification standards are set out on pure peptides, and facility and shipping details are available on our information page.

Sermorelin is one of the oldest and best-characterised GHRH fragments available to researchers, which makes it a deceptively easy compound to under-respect: the sequence is simple, the mechanism is textbook, and nearly every failure point is procedural rather than chemical. A clipped N-terminus, a certificate from the wrong lot, a vial that rode warm for two days. None of those announce themselves. The sermorelin in the vial is only ever as meaningful as the paperwork that describes it and the freezer that holds it. All products are sold for laboratory research use only and are not for human consumption.